Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $9.43.

Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $5.00 price objective (down previously from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Stephens initiated coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective on the stock. Finally, Royal Bank of Canada restated an “outperform” rating and set a $8.00 price objective (down previously from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th.

Insiders Place Their Bets

In other Pyxis Oncology news, CFO Pamela Ann Connealy bought 88,850 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were purchased at an average price of $1.96 per share, with a total value of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares in the company, valued at $2,350,320.28. This represents a 8.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in shares of Pyxis Oncology by 92.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock worth $1,031,000 after buying an additional 149,522 shares in the last quarter. Rhumbline Advisers purchased a new position in Pyxis Oncology in the second quarter valued at about $216,000. American Century Companies Inc. raised its holdings in Pyxis Oncology by 56.0% in the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock worth $193,000 after purchasing an additional 20,901 shares in the last quarter. Schulhoff & Co. Inc. lifted its position in Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock valued at $4,425,000 after acquiring an additional 743,499 shares in the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Trading Up 3.5 %

Shares of PYXS stock opened at $1.76 on Tuesday. The company’s fifty day moving average price is $2.52 and its 200-day moving average price is $3.13. The stock has a market cap of $104.66 million, a PE ratio of -1.71 and a beta of 1.06. Pyxis Oncology has a 12 month low of $1.49 and a 12 month high of $6.85.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.